ALOPEXX Oncology
About ALOPEXX Oncology
Founded in 2011, Alopexx is a science-driven Investment, Management and Development Company. We invest in novel health care technologies at all stages of development. We have a large, experienced team with expertise at all stages of product development.YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CEO: Daniel R. Vlock
Founder and Principal: Christine de los Reyes
Founder and Principal: Deborah Ramsdell
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW ALOPEXX ENTERPRISES:
Tweets by Alopexx Enterprises
2 articles about ALOPEXX Oncology
-
Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia
3/4/2020
Alopexx Oncology, LLC announced today that it has entered into an exclusive license agreement with Beijing Shenogen Pharma Group to develop and commercialize DI-Leu16-IL2 in China and other parts of Asia.
-
ALOPEXX Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society of Hematology Annual Meeting
12/7/2016